PMID- 31693900
OWN - NLM
STAT- MEDLINE
DCOM- 20200924
LR  - 20210715
IS  - 2211-1247 (Electronic)
VI  - 29
IP  - 6
DP  - 2019 Nov 5
TI  - Distinct Polymorphisms in HLA Class I Molecules Govern Their Susceptibility to 
      Peptide Editing by TAPBPR.
PG  - 1621-1632.e3
LID - S2211-1247(19)31271-9 [pii]
LID - 10.1016/j.celrep.2019.09.074 [doi]
AB  - Understanding how peptide selection is controlled on different major 
      histocompatibility complex class I (MHC I) molecules is pivotal for determining 
      how variations in these proteins influence our predisposition to infectious 
      diseases, cancer, and autoinflammatory conditions. Although the intracellular 
      chaperone TAPBPR edits MHC I peptides, it is unclear which allotypes are 
      subjected to TAPBPR-mediated peptide editing. Here, we examine the ability of 97 
      different human leukocyte antigen (HLA) class I allotypes to interact with 
      TAPBPR. We reveal a striking preference of TAPBPR for HLA-A, particularly for 
      supertypes A2 and A24, over HLA-B and -C molecules. We demonstrate that the 
      increased propensity of these HLA-A molecules to undergo TAPBPR-mediated peptide 
      editing is determined by molecular features of the HLA-A F pocket, specifically 
      residues H114 and Y116. This work reveals that specific polymorphisms in MHC I 
      strongly influence their susceptibility to chaperone-mediated peptide editing, 
      which may play a significant role in disease predisposition.
CI  - Copyright (c) 2019 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Ilca, F Tudor
AU  - Ilca FT
AD  - Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge 
      CB2 1QP, UK.
FAU - Drexhage, Linnea Z
AU  - Drexhage LZ
AD  - Faculty of Biology, University of Freiburg, Schaenzlestrasse 1, 79104 Freiburg, 
      Germany.
FAU - Brewin, Gemma
AU  - Brewin G
AD  - Tissue Typing Laboratory, Box 209, Level 6 ATC, Cambridge University Hospitals, 
      NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0QQ, 
      UK.
FAU - Peacock, Sarah
AU  - Peacock S
AD  - Tissue Typing Laboratory, Box 209, Level 6 ATC, Cambridge University Hospitals, 
      NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0QQ, 
      UK.
FAU - Boyle, Louise H
AU  - Boyle LH
AD  - Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge 
      CB2 1QP, UK. Electronic address: lhb22@cam.ac.uk.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cell Rep
JT  - Cell reports
JID - 101573691
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immunoglobulin Allotypes)
RN  - 0 (Immunoglobulins)
RN  - 0 (Membrane Proteins)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Molecular Chaperones)
RN  - 0 (Peptides)
RN  - 0 (TAPBPL protein, human)
RN  - 0 (tapasin)
SB  - IM
MH  - Antigen Presentation
MH  - HEK293 Cells
MH  - HLA-A Antigens/*chemistry/*metabolism
MH  - HLA-A2 Antigen/chemistry/metabolism
MH  - HLA-A24 Antigen/chemistry/metabolism
MH  - HLA-B Antigens/genetics/metabolism
MH  - HLA-C Antigens/metabolism
MH  - HeLa Cells
MH  - Histocompatibility Antigens Class I/*chemistry/genetics/*metabolism
MH  - Humans
MH  - Immunoglobulin Allotypes
MH  - Immunoglobulins/genetics/*metabolism
MH  - Membrane Proteins/genetics/*metabolism
MH  - Membrane Transport Proteins/genetics/metabolism
MH  - Molecular Chaperones/chemistry/metabolism
MH  - Peptides/chemistry/metabolism
MH  - Polymorphism, Genetic
MH  - Protein Binding
MH  - Protein Domains/genetics
PMC - PMC7057265
OTO - NOTNLM
OT  - HLA
OT  - MHC
OT  - TAPBPR/TAPBPL
OT  - antigen processing and presentation
OT  - polymorphism
COIS- Part of the work described in this paper has been the subject of a patent 
      application filed by Cambridge Enterprise, a wholly owned subsidiary of the 
      University of Cambridge. The patent application number is PCT/EP2019/051907, with 
      F.T.I. and L.H.B. as named inventors.
EDAT- 2019/11/07 06:00
MHDA- 2020/09/25 06:00
PMCR- 2019/11/05
CRDT- 2019/11/07 06:00
PHST- 2019/03/11 00:00 [received]
PHST- 2019/07/28 00:00 [revised]
PHST- 2019/09/25 00:00 [accepted]
PHST- 2019/11/07 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2020/09/25 06:00 [medline]
PHST- 2019/11/05 00:00 [pmc-release]
AID - S2211-1247(19)31271-9 [pii]
AID - 10.1016/j.celrep.2019.09.074 [doi]
PST - ppublish
SO  - Cell Rep. 2019 Nov 5;29(6):1621-1632.e3. doi: 10.1016/j.celrep.2019.09.074.